TII
21.4.2021 14:47:13 CEST | Business Wire | Press release
Technology Innovation Institute (TII), the applied research pillar of Abu Dhabi’s Advanced Technology Research Council (ATRC), today announced that its Secure Systems Research Centre (SSRC) has partnered with Khalifa University, Georgia Institute of Technology, Tampere University and University of Applied Sciences and Arts of Southern Switzerland (SUPSI). Secure Systems Research Centre also recently announced that it had partnered with Purdue University.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210421005624/en/
The announcement of these collaborations is the latest in a series of announcements by Technology Innovation Institute since the first Advanced Technology Research Council board meeting in August 2020. Secure Systems Research Centre is one of the initial seven dedicated research centres at Technology Innovation Institute. The strategic partnerships will advance breakthroughs in the field of secure systems and its sub-disciplines across crucial projects.
The partnership with the UAE’s prestigious Khalifa University spans four major projects, the first of which explores opportunities to use machine learning for exfiltration detection on android smartphones. The second project involves the development of solutions in secure communications for power-constrained wireless mesh networks while the third investigates physical wireless security and routing protocols on drone communications. Finally, the last project looks at physical layer security for diverse unmanned aerial vehicle (UAV)-ground wireless networks. This project seeks to evaluate the vulnerabilities of these networks and propose efficient solutions to mitigate system weakness.
The partnership with Georgia Institute of Technology in the United States encompasses a project that will devise a theory for constructing attack-resilient software that can address real-time constraints in cyber-physical and autonomous systems (CPAS). The research team will demonstrate techniques that enhance the security of CPAS software and platforms, with a focus on drones. The cooperation with Tampere University in Finland comprises of a project related to critical infrastructure security. This project will uncover methods to reduce an attacker’s ability to infiltrate, steal and manipulate data in critical infrastructure. This research has prominent use-cases in areas such as drone deployment, emergency services, infrastructure on demand, and smart city data processing.
The partnership with Switzerland’s SUPSI will explore AI-based secure autonomous navigation on Nano-UAVs, focusing on security, autonomy, and resilience. The team aims to enable secure communication and computation onboard resource-constrained (i.e., computation, memory, power, and payload) cyber-physical systems (CPSs) by leveraging machine learning, deep learning, and advanced artificial intelligence techniques.
Speaking on the partnership announcements, Dr Shreekant (Ticky) Thakkar, Chief Researcher at Secure Systems Research Centre leading the Secure Autonomous Computing work, said: “Our world is more connected – and more vulnerable to cyberattacks. Smart cities, transportation and other critical infrastructure, require the highest levels of defence against these attacks. The partnerships and crucial projects that we have announced with prestigious global institutions will no doubt have far-reaching advancements in secure and resilient autonomous system solutions that encompass platforms, systems software, communications, applications, and data integrity.”
In March 2021, Technology Innovation Institute announced that Secure Systems Research Centre has partnered with Purdue University, a world-renowned US-based public research university, to collaborate on a three-year sophisticated cybersecurity project to ensure unmanned aerial vehicles can be used safely and efficiently in urban operations.
For more information about Technology Innovation Institute (TII) please visit www.tii.ae
*Source: AETOSWire
View source version on businesswire.com: https://www.businesswire.com/news/home/20210421005624/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 16:13:00 CEST | Press release
In a head-to-head benchmark, a leading general-purpose LLM was confidently wrong 35% of the time on regulatory dates. Archer Evolv™ shipped zero errors. For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and mo
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 16:08:00 CEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
Interactive Brokers Expands Access to Korean Equities with Launch of Nextrade ATS30.6.2026 16:00:00 CEST | Press release
IB SmartRouting℠ Routes Orders to the Best Available Price Between KRX and Nextrade Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced the launch of select Korean equities through Nextrade, South Korea's first Alternative Trading System (ATS). The addition of Nextrade builds on Interactive Brokers' earlier launch of the Korea Exchange (KRX), through which it became the first major US-based broker to provide global investors with direct access to Korean equities. Clients trading on Nextrade benefit from significantly extended trading hours and access to additional liquidity. Interactive Brokers has enabled IB SmartRouting℠ across both the Korea Exchange (KRX) and Nextrade, automatically routing orders to the venue offering the best price. This helps clients achieve best execution while providing greater flexibility and more opportunities to participate in one of Asia's most dynamic equity markets. Korea's equity market ranks among the top global exchanges by
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom